Ausgabe 3/2016
Inhalt (15 Artikel)
Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell lines
Lea S. Flocke, Robert Trondl, Michael A. Jakupec, Bernhard K. Keppler
Convection-enhancement delivery of liposomal formulation of oxaliplatin shows less toxicity than oxaliplatin yet maintains a similar median survival time in F98 glioma-bearing rat model
Minghan Shi, David Fortin, Benoit Paquette, Léon Sanche
Microtubule-stabilizing properties of the avocado-derived toxins (+)-(R)-persin and (+)-(R)-tetrahydropersin in cancer cells and activity of related synthetic analogs
Jessica J. Field, Arun Kanakkanthara, Darby G. Brooke, Saptarshi Sinha, Sushila D. Pillai, William A. Denny, Alison J. Butt, John H. Miller
Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors
Manisha H. Shah, Paul Lorigan, Mary E. R. O’Brien, Frank V. Fossella, Kathleen N. Moore, Shailender Bhatia, Maurice Kirby, Penella J. Woll
Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison
Anne-Charlotte Dubbelman, Cynthia M. Nijenhuis, Robert S. Jansen, Hilde Rosing, Hitoshi Mizuo, Shinki Kawaguchi, David Critchley, Robert Shumaker, Jan H. M. Schellens, Jos H. Beijnen
A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers
Andrew L. Coveler, Andrew H. Ko, Daniel V. T. Catenacci, Daniel Von Hoff, Carlos Becerra, Nancy C. Whiting, Jing Yang, Brian Wolpin
A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors
B. Milojkovic Kerklaan, S. Slater, M. Flynn, A. Greystoke, P. O. Witteveen, M. Megui-Roelvink, F. de Vos, E. Dean, L. Reyderman, L. Ottesen, M. Ranson, M. P. J. Lolkema, R. Plummer, R. Kristeleit, T. R. J. Evans, J. H. M. Schellens
Exposure–safety–efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study
Neeraj Gupta, Richard Labotka, Guohui Liu, Ai-Min Hui, Karthik Venkatakrishnan
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
Toshio Shimizu, Takashi Seto, Fumihiko Hirai, Mitsuhiro Takenoyama, Kaname Nosaki, Junji Tsurutani, Hiroyasu Kaneda, Tsutomu Iwasa, Hisato Kawakami, Kazuo Noguchi, Takashi Shimamoto, Kazuhiko Nakagawa
Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer
Shivaani Kummar, James L. Wade, Amit M. Oza, Daniel Sullivan, Alice P. Chen, David R. Gandara, Jiuping Ji, Robert J. Kinders, Lihua Wang, Deborah Allen, Geraldine O’Sullivan Coyne, Seth M. Steinberg, James H. Doroshow
Effect of regulation reform on clinical trials for registering novel therapeutic agents in Taiwan: a chronological analysis
I-Chen Sun, Horng-Shing Shy, Tzu-Ya Liao
RRx-001, A novel dinitroazetidine radiosensitizer
Bryan Oronsky, Jan Scicinski, Shoucheng Ning, Donna Peehl, Arnold Oronsky, Pedro Cabrales, Mark Bednarski, Susan Knox
Targeted therapies in gastric cancer treatment: where we are and where we are going
Gianluca Tomasello, Michele Ghidini, Wanda Liguigli, Margherita Ratti, Laura Toppo, Rodolfo Passalacqua
Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget’s disease
Satomi Watanabe, Masayuki Takeda, Takayuki Takahama, Tsutomu Iwasa, Junji Tsurutani, Junko Tanizaki, Toshio Shimizu, Kazuko Sakai, Yoshitaka Wada, Noritaka Isogai, Kazuto Nishio, Kazuhiko Nakagawa
A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib
Linda Mahjoubi, Anas Gazzah, Benjamin Besse, Ludovic Lacroix, Jean-Charles Soria